Select a page
DARVAC: Inserm impact Santé

DARVAC: Inserm impact Santé

Team 3 from INCIT Lab Inserm U1302 (Nantes) is part of the Inserm Impact Santé project DARVAC "Development of vaccines offering innovative early protection against non-viral cancers" based on ghost (Dark) proteins. The project is led by Jerome Galon, with Michel...
New publication - Team 3

New publication - Team 3

Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer OncoImmunology Volume 11, 2022 - Issue 1 Authors : Kathleen Ducoin, Romain Oger, Linda Bilonda Mutala, Cécile Deleine, Nicolas Jouand, Juliette Desfrançois, Juliette Podevin,...
New research area Team 2

New research area Team 2

Response to Immunotherapies in metastatic melanoma could be predicted by visible sun exposure traces around the scar of the primary melanoma, identified by artificial intelligence algorithms JCO Precis Oncol....